Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

3.770 -0.050 (-1.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adma Biologics

< Previous 1 2 3 4 Next >
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance
From ADMA Biologics, Inc.
Via GlobeNewswire
Jim Cramer Says Forget AT&T, This 'Class Of The Field' Communications Stock Is Better
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ADMA Biologics, Inc. (NASDAQ: ADMA) is a "great spec, but it is losing money hand over fist. I think it’s very binary. 
Via Benzinga
Bulls In A Bear Market: These 10 Stocks Clocked Gains In Excess Of 100% In 2022
2022 would go down as one of the worst years for the financial markets. The sell-off has been all-pervasive, with stocks, bonds and cryptos all selling off indiscriminately. Even as high-fliers like... 
Via Benzinga
Looking Into ADMA Biologics's Return On Capital Employed
Via Benzinga
Recap: ADMA Biologics Q2 Earnings
  ADMA Biologics (NASDAQ:ADMA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Proposed Public Offering of Common Stock
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million 
From ADMA Biologics, Inc.
Via GlobeNewswire
Why Cano Health Shares Are Trading Sharply Lower; Here Are 29 Stocks Moving Premarket
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 59% to $0.1619 in pre-market trading after dipping 40% on Wednesday. Fast Radius recently filed voluntary petitions for relief under Chapter 11. 
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares climbed 172% to $0.2769 after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions related to the company's... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers NexImmune (NASDAQ:NEXI) shares rose 38.8% to $0.7 during Thursday's pre-market session. The market value of their outstanding shares is at $16.9 million. 
Via Benzinga
Coupang, Rivian Automotive And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
A Preview Of ADMA Biologics's Earnings
ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that ADMA... 
Via Benzinga
ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC
From ADMA Biologics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
7 A-Rated Stocks to Buy for Less Than $10
While stocks under $10 don't carry the cache of blue-chip stocks, the returns that they offer can be enticing. 
Via InvestorPlace
7 Top-Rated Biotech Stocks to Buy for Q4
A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Stocks That Made New Highs On Friday, Aug. 19
On Friday, in spite of the stock market being down, there were several stocks that actually made new highs. 
Via Talk Markets
ADMA Biologics: Earnings Outlook
  ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that ADMA... 
Via Benzinga
Why ADMA Biologics Shares Are Rising Today
ADMA Biologics Inc (NASDAQ: ADMA) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration approval for its sixth plasma collection center. 
Via Benzinga
Looking Into ADMA Biologics's Return On Capital Employed
Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter. 
Via Benzinga
Recap: ADMA Biologics Q1 Earnings
ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated... 
Via Benzinga
Earnings Outlook For ADMA Biologics
ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ADMA... 
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.